Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:18:02.220Z.
Consensus retrieved: 2026-10-06T15:04:27.489Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:18:02.220Z.
Quote observation: 2026-10-06T19:14:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8dd4f1084baaf1fdd631c8004248db7003b46672aad8e0139030c30c223f55df
Forward PE Ratio (N/A) = Dated Quote Price ($2.69) / Consensus Forward EPS ($-3.62)
FORWARD PE RATIO
N/A
PAVmed Inc.
Market Cap
$17.14M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| PAVmed Inc. (PAVM) | $17.14M | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.17M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.11M | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.99M | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.77M | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.70M | N/A |
| Cosmos Health Inc. (COSM)vs › | $18.17M | N/A |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.67M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $18.41M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.69, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.62 | $-4.26 – $-2.98 | 1 | n/m |
| 2027-12-31 | $-1.98 | $-2.33 – $-1.63 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
